LINDSEY LAWRENCE: Open Payments
NPI 1477050607 · WILMINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,461 in 54 payments from 11 companies in 2025. Trend: 2023 $3,086 · 2024 $2,145 · 2025 $1,461
Food & beverage: $1,461
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 21 | $426 |
| Otsuka America Pharmaceutical, Inc. | 17 | $384 |
| Alkermes, Inc. | 5 | $183 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $149 |
| Supernus Pharmaceuticals, Inc. | 1 | $125 |
| Braeburn Inc. | 1 | $101 |
| Luye Pharma (USA) Ltd. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
Products named: REXULTI, HETLIOZ, FANAPT, CAPLYTA, Qelbree, LYBALVI, BRIXADI, ABILIFY ASIMTUFII.
Industry payments across NC — which companies pay providers there.
